Evidence map›Paper›PMID 34771744›Full record

ReviewCancers2021

Transcriptomics, Epigenetics, and Metabolomics of Primary Aldosteronism.

Ariadni Spyroglou, George P Piaditis, Gregory Kaltsas, Krystallenia I Alexandraki

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ariadni Spyroglou2nd Department of Surgery, Aretaieio Hospital Athens, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
George P PiaditisDepartment of Endocrinology and Diabetes Center, G. Gennimatas General Hospital, 11527 Athens, Greece.
Gregory KaltsasEndocrine Unit, First Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Krystallenia I Alexandraki2nd Department of Surgery, Aretaieio Hospital Athens, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0003-2398-6768
National and Kapodistrian University of Athens · GRGeneral Hospital of Athens G. Genimatas · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrimary aldosteronism (PA) is the most common cause of endocrine hypertension, mainly caused by aldosterone-producing adenomas or hyperplasia; understanding its pathophysiological background is important in order to provide ameliorative treatment strategies. Over the past several years, significant progress has been documented in this field, in particular in the clarification of the genetic and molecular mechanisms responsible for the pathogenesis of aldosterone-producing adenomas (APAs).

methodsSystematic searches of the PubMed and Cochrane databases were performed for all human studies applying transcriptomic, epigenetic or metabolomic analyses to PA subjects. Studies involving serial analysis of gene expression and microarray, epigenetic studies with methylome analyses and micro-RNA expression profiles, and metabolomic studies focused on improving understanding of the regulation of autonomous aldosterone production in PA were all included.

resultsIn this review we summarize the main findings in this area and analyze the interplay between primary aldosteronism and several signaling pathways with differential regulation of the RNA and protein expression of several factors involved in, among others, steroidogenesis, calcium signaling, and nuclear, membrane and G-coupled protein receptors. Distinct transcriptomic and metabolomic patterns are also presented herein, depending on the mutational status of APAs. In particular, two partially opposite transcriptional and steroidogenic profiles appear to distinguish APAs carrying a

conclusionsThese findings can substantially contribute to the development of personalized treatment in patients with PA.

Indexed as

epigeneticsmetabolomicsprimary aldosteronismtranscriptomics

Identifiers

PMID34771744
PMCPMC8583505
OpenAlexW3212250046

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.